Wuxi Biologics Cayman Inc

Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. It operates through the Biologics and XDC segments. The company was founded on February 27, 2014, and is headquartered in Wuxi, China.

Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI , Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a healthier future.

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

Multiple successful 16,000L PPQ runs highlight that disposable manufacturing can achieve similar performance as traditional stainless reactors GMP Authorizations by HPRA demonstrate that new global sites have built strong world-class regulatory and quality system  DUNDALK, Ireland , Dec. 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced major accomplishments at its cutting-edge greenfield site in Dundalk, Ireland. The site has successfully completed multiple 16,000-liter Process Performance Qualification (PPQ) runs at its MFG7 drug substance suite.

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

LEVERKUSEN, Germany , Nov. 13, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it will enhance its drug product (DP) capabilities at the company's facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology. Construction of the new line will optimize the design of the Leverkusen facility's manufacturing layout to be more efficient for multi-product CRDMO use.

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

SHANGHAI , Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. The platform, specialized in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the endogenous GS gene in CHO cells.

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

HONG KONG , Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards for the fourth year in a row. The prestigious honor recognizes the company's unwavering commitment to sustainable practices as well as its effective approaches to driving innovation and efficiency through green technology.

WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

HONG KONG , Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this year.

WuXi Biologics Included in Hang Seng ESG 50 Index

By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity improvement compared to the traditional fed-batch process The competitive performance achieved through the utilization of both WuXiUI™ and the proprietary platform cell culture media MagniCHO™ led to significant reduction in overall DS manufacturing COGS The consistent performance of WuXiUI™ – from small scales to 2,000L GMP manufacturing – is a testament to the advancement of the technology as a mature and robust platform capable of significantly improving the cost-effectiveness of biologics production SHANGHAI , Aug. 30, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully accomplished 2,000L drug substance (DS) GMP manufacturing by utilizing its proprietary ultra-intensified fed-batch bioprocessing platform WuXiUI™. The platform achieved a titer of 18 g/L, a 4-fold increase compared to conventional fed-batch process, demonstrating the high efficiency of WuXiUI™ in improving productivity.

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ET Company Participants Lina Fan - Senior Vice President, Head of Investor Relations Chris Chen - Chief Executive Officer Ming Tu - Chief Financial Officer, Executive Vice President Ziyi Chen - China Healthcare Analyst, Goldman Sachs Conference Call Participants Chen Chen - UBS Samuel Isaly - Exome Asset Management Jingyi Li - Harding Loevner Ziyi Chen Great. Good morning and good evening, global investors.

WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript

Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, including 4 from late-phase and commercial stageClient's molecule recently acquired by MNC, highlighting a potential best-in-class CD3 asset utilizing three of our proprietary technology platformsTotal integrated projects of 742, one of the largest portfolios of complex biologicsSuccessful EMA inspections of 13 products and FDA inspections of 2 products in 1H24 HONG KONG , Aug. 21, 2024 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 ("Reporting Period"). Financial Highlights Revenue: The Group's revenue for the Reporting Period matches that of the first half of 2023, totaling RMB 8,574.2 million, with a year-on-year (YoY) increase of 1.0%.

WuXi Biologics Reports Solid 2024 Interim Results

Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ Collaboration is a three-year and potentially multi-TCR program partnership SHANGHAI and MUNICH , Aug. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Medigene AG (Medigene, FSE: MDG1, Prime Standard) today announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. The collaboration combines the respective expertise of each company with Medigene's 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics' unique anti-CD3 mAb, its industry leading TCE platform and proprietary bispecific antibody platform WuXiBody™.

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. The collaboration combines the respective expertise of each company with Medigene's 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics' unique anti-CD3 mAb, its industry-leading TCE platform and proprietary bispecific antibody platform WuXiBody™.

Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

WUXI and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities and Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA), demonstrating the company's commitment to meeting rigorous international industry quality standards across its global network. Following comprehensive inspections of the company's facilities– specifically MFG1, MFG2, MFG5, and DP1 in Wuxi– EMA GMP certificates were issued for commercial and New Drug Application (NDA)-ready manufacturing and services for eight biologics, an endorsement to the company's capabilities in providing such services for global clients.

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas emissions in 2023 since 2020.

WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

HONG KONG, March 26, 2024 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").

WuXi Biologics Reports Solid 2023 Annual Results

SHANGHAI , March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'. Based on data reported through CDP's 2023 questionnaire, WuXi Biologics achieved a score of 'A' in the Water Security category, ranking it in the top 2% of the more than 23,000 companies evaluated.

WuXi Biologics Named to CDP 'A List' for Water Security

SHANGHAI , March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-". CDP runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact.

WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

Alibaba

JD.com

Li Auto Inc.

NetEase

Since its launch in 1969, the Hang Seng has always risen in the dragon years, with gains averaging around 14%. But any rally this time could be hampered by uncertainties over the U.S. presidential election and interest rate policy.

Hoping For Better Luck, HK Stocks Enter The Year Of The Dragon

Named Top-Rated for fourth consecutive year Committed to generating long-term value for all stakeholders SHANGHAI , Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized as a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics' Environmental, Social and Governance (ESG) Ratings, marking the fourth consecutive year the company has achieved this honor. Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with the development and implementation of responsible investment strategies.

WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

Shares of the WuXi family of companies extended losses amid concerns that a proposed bill in the U.S. would block the U.S. government from doing business with some Chinese biotechnology companies.

WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill

-  First manufacturing run successful for MFG7 facility at the Ireland site-  Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland , Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully completed the first manufacturing run at its drug substance facility MFG7, paving the way for large-scale commercial manufacturing projects at this Ireland site. The manufacturing run reached 16,000-liter scale by combining four 4,000-liter single-use bioreactors.

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

-  WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients -  WuXiaADCC PLUSTM is derived from WuXi Biologics' highly-vetted WuXiaTM cell line platform SHANGHAI , Jan. 24, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched WuXiaADCC PLUSTM, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response (Figure 1). ADCC is recognized as a crucial mechanism underlying targeted antibody-based immunotherapy approaches.

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

SHANGHAI , Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the developability characteristics of bispecifics – was granted by the U.S. Patent and Trademark Office. This also marks that WuXiBodyTM has been granted patents in the U.S., Japan and China.

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people when fully operational. WORCESTER, Mass.

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

Identified as a global sustainability leader by S&P Global Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, identified as a sustainability leader by S&P Global through its Corporate Sustainability Assessment (CSA). The S&P Global CSA is an annual evaluation of companies' sustainability practices, covering more than 10,000 companies from around the world.

News for Wuxi Biologics Cayman Inc Stock (WXXWY)